STOCK TITAN

Genelux Corporation Reports Third Quarter Financial Results and Provides Business Updates

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Genelux (NASDAQ: GNLX) reported a third-quarter 2026 net loss of $10.285 million while advancing its Olvi-Vec ovarian and lung cancer programs. Loss per share was $0.23 versus $0.21 a year earlier; the prior-year net loss was $7.950 million. Research and development expenses rose to $6.909 million from $4.741 million. October and November stock sales raised $5.1 million net, bringing pro forma cash and investments to $15.5 million, which the company expects to fund operations into first-quarter 2027.

Genelux expects Phase 3 OnPrime ovarian cancer topline data in second-half 2026 and lung cancer dose-escalation updates by year-end 2026. A published Phase 1b/2 case report described one small-cell lung cancer patient with an 84.6% reduction in target lesion size, 16.7 months without disease progression and a 14.3-month response duration. Phase 2 VIRO-25 continues evaluating Olvi-Vec in recurrent non-small-cell lung cancer.

Loading...
Loading translation...
5 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 9 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointATM common-stock sales raised $5.1 million net in October and November, bringing pro forma liquidity to $15.5 million. 6% of market cap
  • Moderate point. Forward-looking: it has not happened yet and may not happen.OnPrime Phase 3 ovarian cancer topline data are expected in second-half 2026.
  • Minor pointOne SCLC case showed 84.6% target-lesion reduction, 16.7-month progression-free survival and 14.3-month response duration, exceeding first-line-treatment results.
  • Minor point. Forward-looking: it has not happened yet and may not happen.SCLC and NSCLC dose-escalation updates are expected by year-end 2026 to support systemic dose selection.
  • Minor pointTotal assets increased to $20.612 million at September 30, 2026, from $19.027 million at December 31, 2025.

Negative

  • Moderate pointThird-quarter net loss widened to $10.285 million, or $0.23 per share, from $7.950 million, or $0.21 per share.
  • Moderate pointThird-quarter R&D expenses rose to $6.909 million from $4.741 million, primarily reflecting increased Phase 3 trial costs.
  • Moderate pointTotal cash and marketable securities declined to $10.449 million at September 30, 2026, from $14.648 million at year-end 2025.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Pro forma liquidity is expected to fund operations into first-quarter 2027.
  • Moderate pointATM financing issued common stock, diluting existing shareholders.
  • Moderate pointAccounts payable and accrued expenses increased to $8.386 million from $4.358 million at year-end 2025.
  • Moderate pointStockholders' equity declined to $9.178 million at September 30, 2026, from $11.544 million at year-end 2025.
2 minor points
  • Minor pointThird-quarter G&A expenses increased to $3.488 million from $3.453 million a year earlier.
  • Minor pointWeighted-average shares rose to 45,308,316 in third-quarter 2026 from 37,893,314 a year earlier.

News Explained

Genelux raised $5.1 million net in October and November by selling common stock through its at-the-market program, which allows gradual sales of new shares at prevailing prices; those new shares increase the share base and dilute existing holders’ ownership percentages.

Key Figures

Pro forma cash and investments: $15.5 million ATM net proceeds: $5.1 million Expected funding runway: Into the first quarter of 2027 +5 more
Pro forma cash and investments
$15.5 million
Following October and November ATM activity
ATM net proceeds
$5.1 million
Common stock sales in October and November
Expected funding runway
Into the first quarter of 2027
Based on combined cash, cash equivalents, marketable securities and restricted cash
Research and development expenses
$6.9 million vs. $4.7 million
Three months ended September 30, 2026 and 2025, respectively
Net loss
$10.3 million vs. $8.0 million
Three months ended September 30, 2026 and 2025, respectively
Net loss per share
$0.23 vs. $0.21
Three months ended September 30, 2026 and 2025, respectively
OnPrime topline data timing
Expected in the second half of 2026
Phase 3 ovarian cancer registrational trial
Target lesion size reduction
84.6%
Single-patient Phase 1b/2 SCLC case report

Previous Earnings Reports

2 past events · Latest: Aug 13
Same Type 2 events
  1. Aug 13

    Q2 earnings

    24h Move
    +4.2%

    Phase 3 readout remained on track; $18.7 million liquidity supported operations into 1Q27.

  2. May 07

    Q1 earnings

    24h Move
    +9.9%

    Reported $26.3 million cash, 1Q27 runway, and Phase 3 ovarian-trial data expected in 2H26.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

at-the-market, progression-free survival, duration of response, immune checkpoint inhibitor
4 terms
at-the-market financial
"under the Company’s at-the-market (ATM) sales agreement"
"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.
progression-free survival medical
"a progression-free survival (PFS) of 16.7 months"
Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.
duration of response medical
"a duration of response (DOR) of 14.3 months"
Duration of response is the length of time a patient’s condition stays improved after a treatment until it starts to worsen again; think of it as how long a freshly charged battery continues to power a device. For investors, longer duration of response implies a treatment provides sustained benefit, which can boost a drug’s commercial value, support stronger regulatory labeling and payer coverage, and reduce the need for additional therapies.
immune checkpoint inhibitor medical
"platinum-based chemotherapy and an immune checkpoint inhibitor (ICI)"
An immune checkpoint inhibitor is a type of medicine that helps the body's immune system recognize and attack cancer cells more effectively. It works by blocking certain signals that cancer uses to hide from immune defenses, allowing the immune system to target tumors. This breakthrough has led to new cancer treatments, making immune checkpoint inhibitors an important area of growth and innovation in the healthcare industry.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 --

-- Recently published Phase 1b/2 OLVI-VEC-202-SCLC case report extends evidence for Olvi-Vec’s platinum re-sensitization mechanism beyond ovarian cancer to systemic delivery in lung cancer --

-- Olvi-Vec systemic development programs continue to advance in SCLC and NSCLC, with additional dose-escalation updates expected by year-end 2026 --

-- $15.5 million in pro forma cash and investments, including $5.1 million from recent activity under the Company’s at-the-market (ATM) sales agreement; expected to fund operations into 1Q27 --

WESTLAKE VILLAGE, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2026 and provided general business updates.

“We continue to make meaningful progress across our clinical programs as we advance toward anticipated Phase 3 OnPrime topline data and additional lung cancer updates," said Thomas Zindrick, President, CEO and Chairman of Genelux. "We were also encouraged by the recent publication of a deep and durable response in a platinum-relapsed small cell lung cancer patient following systemic Olvi-Vec administration, which further supports the potential of our systemic approach and the opportunity to broaden the clinical utility of the program across lung cancer treatment settings. At the same time, we have continued to advance the manufacturing, operational and commercial capabilities needed to support the next phase of growth.”

Clinical Program Highlights

Olvi-Vec in Platinum-Resistant/Refractory Ovarian Cancer:
Genelux is advancing Olvi-Vec toward potential registration in platinum-resistant/refractory ovarian cancer (PRROC), where treatment options remain limited. Ovarian cancer is the 5th leading cause of cancer-related deaths among women, and more than 70% of U.S. patients will either not respond to or relapse after frontline platinum-based therapy (NIH Ovarian Cancer Fact Sheet 2022).

Olvi-Vec is delivered intraperitoneally to achieve high, localized dosing within the peritoneal cavity, with the goal of driving anti-tumor activity and restoring sensitivity to platinum-based chemotherapy.

  • OnPrime/GOG-3076 (NCT05281471) is an ongoing multi-center, randomized, open-label Phase 3 registrational trial being conducted at sites across the United States, with topline data anticipated in the second half of 2026.
  • The trial is evaluating Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab against an active comparator arm of physician's choice of chemotherapy and bevacizumab in women with PRROC (including fallopian tube and primary peritoneal cancers). 

Olvi-Vec in Lung Cancer:
Genelux is advancing two systemic Olvi-Vec trials in lung cancer, extending the platform beyond intraperitoneal delivery and into a wider range of solid tumors. Data from the dose-escalation cohorts in both studies are intended to support selection of a recommended systemic dose for further development in lung cancer and in additional systemic indications.

  • In September 2026, Genelux announced the publication of a case report from the Phase 1b/2 OLVI-VEC-202-SCLC trial in which a platinum-relapsed small cell lung cancer patient achieved a deep and durable partial objective response (84.6% reduction in target lesion size), a progression-free survival (PFS) of 16.7 months and a duration of response (DOR) of 14.3 months, exceeding those observed during her first-line platinum-based treatment. 
    • These findings support the hypothesis that Olvi-Vec-mediated changes in the tumor microenvironment may enhance sensitivity to platinum-based chemotherapy in difficult-to-treat cancers.
    • The report was published in Frontiers in Oncology, a peer-reviewed journal published by Frontiers Media S.A., available here.
  • The Phase 1b/2 study (OLVI-VEC-SCLC-202) in small-cell lung cancer (SCLC) (NCT07136285) is evaluating Olvi-Vec in combination with platinum and etoposide chemotherapy in SCLC patients with platinum-resistant or relapsed disease after failing previous treatment, including frontline platinum and etoposide chemotherapy. The trial is being conducted by the Company’s licensing partner, Newsoara HYK Biopharmaceuticals Co., Ltd., in China.
  • The Phase 2 VIRO-25 study (NCT06463665) is assessing Olvi-Vec in combination with platinum-based chemotherapy and an immune checkpoint inhibitor (ICI) in patients with advanced or metastatic recurrent non-small-cell lung cancer (NSCLC) who failed standard frontline treatment of platinum chemotherapy and an ICI. The trial is being conducted in the United States and is designed to extend Olvi-Vec’s tumor-priming approach into NSCLC.

Further dose‑finding updates from both the Phase 1b/2 SCLC and Phase 2 VIRO-25 NSCLC trials will help refine the systemic dosing regimen ahead of potential registrational development.

Third Quarter 2026 Financial Results

Cash, cash equivalents, marketable securities and restricted cash were $10.4 million as of September 30, 2026. The Company raised an additional $5.1 million in net proceeds from the sale of common stock under the Company’s at-the-market (ATM) sales agreement in October and November, resulting in a pro forma balance of $15.5 million.  The Company expects the combined cash, cash equivalents, marketable securities and restricted cash will fund operations into the first quarter of 2027.

Research and development (R&D) expenses were $6.9 million and $4.7 million for the three months ended September 30, 2026 and 2025, respectively, an increase of $2.2 million. The increase was primarily driven by clinical and regulatory expenses relating to increased clinical trial costs associated with our Phase 3 On Prime/GOG-3076 registrational trial.

General and administrative (G&A) expenses were $3.5 million and $3.5 million for the three months ended September 30, 2026 and 2025, respectively, an increase of $0.04 million. The increase was primarily driven by an increase in stock compensation, partially offset by a decrease in employee compensation and related expenses.

Net loss was $10.3 million or $0.23 per share for the three months ended September 30, 2026, as compared to $8.0 million or $0.21 per share over the same period in 2025.

About Genelux Corporation

Genelux is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Phase 1b/2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet in recurrent small-cell lung cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which Genelux has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “potential,” “expected,” “anticipated,” “continued,” “remain,” “may” or “intended.” Forward-looking statements in this release include, but are not limited to, statements related to Genelux’s future plans and prospects, Genelux’s anticipated cash runway and the sufficiency of its resources to support its planned operations; the timing and likelihood of success of Genelux’s business strategy, as well as plans and objectives of management for future operations including advancing manufacturing, operational and commercial capabilities; the planned timing of Genelux’s data results, clinical updates and dose selection in its ongoing clinical trials and continued development of Olvi-Vec; the potential capabilities advantages, safety and efficacy of Olvi-Vec, including the potential of Olvi-Vec to resensitize tumors to platinum therapy; the potential for the ongoing NSCLC and SCLC trials to support the systemic route of delivery program of Olvi-Vec and expansion of development into other solid tumor types; the potential for Olvi-Vec-mediated changes in the tumor microenvironment to enhance sensitivity to platinum-based chemotherapy in difficult-to-treat cancers; the potential for data from the lung cancer trials to enable the Company to refine a systemic dosing regimen to inform future registrational development; and the potential regulatory requirements and approval pathway of Olvi-Vec. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements. These and other risks are identified under the caption “Risk Factors” in Genelux’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Genelux does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.


 
Genelux Corporation
Condensed Statements of Operations
(in thousands, except share and per share amounts)
(unaudited)
 
 Three Months Ended
 September 30,
  2026   2025 
    
    
Revenues$-  $- 
    
Operating expenses:   
Research and development 6,909   4,741 
General and administrative 3,488   3,453 
Total operating expenses 10,397   8,194 
    
Operating loss (10,397)  (8,194)
    
Other income 112   244 
    
Net loss$(10,285) $(7,950)
    
Net loss per share- Basic and Diluted$(0.23) $(0.21)
    
Weighted-average shares outstanding -   
Basic and Diluted 45,308,316   37,893,314 
    
The accompanying notes are an integral part of these condensed financial statements.


  
Genelux Corporation 
Condensed Balance Sheets 
(in thousands) 
        
 September 30, December 31,
  2026   2025 
 (unaudited)   
ASSETS    
Cash, cash equivalents, and restricted cash$9,445  $5,333 
Marketable securities 1,000   9,262 
Accrued interest 4   53 
Total cash and marketable securities 10,449   14,648 
     
Other assets 10,163   4,379 
Total Assets$20,612  $19,027 
     
LIABILITIES AND STOCKHOLDERS' EQUITY    
Accounts payable and accrued expenses$8,386  $4,358 
Other liabilities 3,048   3,125 
Total Liabilities$11,434  $7,483 
     
Total Stockholders' Equity 9,178   11,544 
       
Total Liabilities and Stockholders' Equity$20,612  $19,027 
     
The accompanying notes are an integral part of these condensed financial statements. 


Investor Contact

Austin Murtagh
Precision AQ
austin.murtagh@precisionaq.com

Media Contact

Ashley Murphy
Precision AQ
ashley.murphy@precisionaq.com

Source: Genelux Corporation


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Genelux expect Olvi-Vec Phase 3 ovarian cancer results?

Genelux expects topline data from the Phase 3 OnPrime/GOG-3076 trial in second-half 2026. The ongoing trial evaluates Olvi-Vec in women with platinum-resistant or refractory ovarian cancer, including fallopian tube and primary peritoneal cancers.

How much cash does Genelux have and how long is it expected to last?

Genelux has $15.5 million in pro forma cash and investments, which it expects to fund operations into first-quarter 2027. That balance includes $5.1 million in net proceeds from common-stock sales under its at-the-market sales agreement in October and November.

What treatments are being compared in Genelux's OnPrime ovarian cancer trial?

OnPrime compares Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab against physician's choice of chemotherapy and bevacizumab. It is a randomized, open-label Phase 3 trial conducted at multiple sites across the United States.

Who is conducting Genelux's SCLC trial and which patients can participate?

Genelux's licensing partner, Newsoara HYK Biopharmaceuticals, is conducting the Phase 1b/2 trial in China. It evaluates Olvi-Vec with platinum and etoposide chemotherapy in small-cell lung cancer patients with platinum-resistant or relapsed disease after previous treatment, including frontline platinum and etoposide chemotherapy.

Keep reading